To explore the specific role of PAK6 in mediating TKI resistance in CML, we generated a lentiviral-mediated shRNA knockdown system with two constructs targeting different sequences of PAK6 and demonstrated that both specifically suppressed PAK6 gene expression at both the RNA and protein levels (up to 80%, Figure 1A and Figure S1A). The gene discussed is PAK6; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.